The BioMe team behind the development of a revolutionary pill (from left) Matthias Thurner, Agnieszka Chomka, Soren Thomsen and Patrick Albers stand in front of the Radcliffe Camera
The article highlights how "a hi-tech pill being developed by a team of Oxford scientists could revolutionise the way doctors test for some diseases".
Further, "with pills expected to cost £2 each, compared to £800 for an endoscopy session, it could herald a breakthrough for the cash-strapped NHS."
BioMe was a former finalist at Venturefest's funding event for investor-ready entrepreneurs, Pitchfest, and has also been shortlisted for The Oxford Trust Enterprise Awards 2016.
Read more
Latest news
The future of Venturefest
After 23 years of successful operation, Venturefest Oxford is entering a new era. READ MORE
Research, industry, and AGI
A transfer of knowledge to industry is a good thing: One purpose of a university is to benefit society by disseminating knowledge, and one way this can be done is by commercialising research. Universities and research institutions are a dynamo for entrepreneurship, and for innovation in large companies. READ MORE
For success in product development – start at square zero
When it comes to the commercial success of a technology-led product, there are a number of factors that come into play along the development journey. Have the regulatory requirements been met? Can the design be produced at a viable cost? Is it possible to ensure the quality of the manufacturing process? The list goes on. READ MORE
Make connections that lead to new investments, new businesses and new ideas in the high-tech sector in Oxfordshire.